Literature DB >> 12662400

Why do general practitioners request rheumatoid factor? A study of symptoms, requesting patterns and patient outcome.

David Sinclair1, Richard G Hull.   

Abstract

BACKGROUND: To investigate the reasons why general practitioners (GPs) request rheumatoid factor (RF) assays, we studied 200 consecutive requests for RF from general practice in 1995.
METHOD: By means of an audit questionnaire, we studied 100 negative, 50 positive and 50 borderline RF results and compared these with the presenting symptoms that prompted the request, the GPs' understanding of the significance of the result, the referral intention and behaviour of the GP, and finally, the patient outcome after 5 years.
RESULTS: There was an 80% response rate. The presenting symptoms closely matched the American Rheumatism Association revised criteria for the classification of rheumatoid arthritis, indicating that the requests were made on valid clinical grounds, with polyarthralgia, morning stiffness and joint pain being the most common. Most GPs considered a negative or positive result to be meaningful, in that a positive RF meant that a referral was more likely than with a negative or borderline result, even in the presence of appropriate symptoms in all three groups. Seventeen to thirty per cent felt that the test excluded or confirmed RA. The result appeared to influence this decision to a greater extent than it should. A 5-year follow-up on these patients showed that 26/40 patients with positive RF were referred, and that 25 of them developed a rheumatic disease of some kind, with 17 patients eventually being diagnosed with RA. Only 17/80 patients with negative RF were referred, the remainder having no autoimmune problem evident after 5 years, 11 of them developing a rheumatic disease, and only three being diagnosed with RA.
CONCLUSIONS: Although this is a locally based study, we believe the conclusions would be applicable to all laboratories and GPs undertaking these tests. RF requests are made on valid clinical grounds by GPs, but there may be an over-reliance on the results as regards referral behaviour. If patients were referred on clinical grounds, this would significantly lengthen consultants' waiting lists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12662400     DOI: 10.1258/000456303763046049

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  6 in total

1.  Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.

Authors:  V P K Nell; K P Machold; T A Stamm; G Eberl; H Heinzl; M Uffmann; J S Smolen; G Steiner
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

2.  Is rheumatoid factor useful in primary care? A retrospective cross-sectional study.

Authors:  Anne Miller; Kamal R Mahtani; Margaret A Waterfield; Anthony Timms; Siraj A Misbah; Raashid A Luqmani
Journal:  Clin Rheumatol       Date:  2013-03-21       Impact factor: 2.980

3.  Referral criteria in early rheumatoid arthritis.

Authors:  Vicki Quincey; R Hull; D Sinclair
Journal:  J R Soc Med       Date:  2004-12       Impact factor: 18.000

4.  Autoimmune markers for the diagnosis of rheumatoid arthritis in primary care: primary care diagnostic technology update.

Authors:  Kamal R Mahtani; Anne Miller; Oliver Rivero-Arias; Carl Heneghan; Christopher P Price; Matthew Thompson; Annette Plüddemann; Raashid Luqmani
Journal:  Br J Gen Pract       Date:  2013-10       Impact factor: 5.386

5.  Primary care challenges in diagnosing and referring patients with suspected rheumatoid arthritis: a national cross-sectional GP survey.

Authors:  Ian C Scott; Navjeet Mangat; Alex MacGregor; Karim Raza; Christian D Mallen; Samantha L Hider
Journal:  Rheumatol Adv Pract       Date:  2018-04-06

6.  A multicentre validation study of a smartphone application to screen hand arthritis.

Authors:  Mark Reed; Broderick Rampono; Wallace Turner; Andreea Harsanyi; Andrew Lim; Shereen Paramalingam; David Massasso; Vivek Thakkar; Maninder Mundae; Elliot Rampono
Journal:  BMC Musculoskelet Disord       Date:  2022-05-09       Impact factor: 2.562

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.